

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI378041

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	Amorsa Therapeutics, Inc.	06/29/2023
RECEIVING PARTY DATA		
Company Name:	ACADIA Pharmaceuticals Inc.	
Street Address:	12830 El Camino Real	
Internal Address:	Suite 400	
City:	San Diego	
State/Country:	CALIFORNIA	
Postal Code:	92130	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16868444
CORRESPONDENCE DATA		
Fax Number:	4142770656	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	4142716560	
Email:	dahausen@michaelbest.com,mkeipdocket@michaelbest.com	
Correspondent Name:	Dorothy A. Hauser	
Address Line 1:	Michael Best & Friedrich LLP	
Address Line 2:	N19 W24133 Riverwood Drive, Ste. 200	
Address Line 4:	Waukesha, WISCONSIN 53188	
ATTORNEY DOCKET NUMBER:	221769-9001-US03	
NAME OF SUBMITTER:	Dorothy Hauser	
SIGNATURE:	Dorothy Hauser	
DATE SIGNED:	07/22/2024	
Total Attachments: 8		
source=221769-9001-US03 As Filed Assignment - ACADIA Pharmaceuticals Inc.#page1.tiff		
source=221769-9001-US03 As Filed Assignment - ACADIA Pharmaceuticals Inc.#page2.tiff		
source=221769-9001-US03 As Filed Assignment - ACADIA Pharmaceuticals Inc.#page3.tiff		
source=221769-9001-US03 As Filed Assignment - ACADIA Pharmaceuticals Inc.#page4.tiff		

source=221769-9001-US03 As Filed Assignment - ACADIA Pharmaceuticals Inc.#page5.tiff

source=221769-9001-US03 As Filed Assignment - ACADIA Pharmaceuticals Inc.#page6.tiff

source=221769-9001-US03 As Filed Assignment - ACADIA Pharmaceuticals Inc.#page7.tiff

source=221769-9001-US03 As Filed Assignment - ACADIA Pharmaceuticals Inc.#page8.tiff

PATENT

REEL: 068048 FRAME: 0954

ASSIGNMENT OF PATENT RIGHTS

WHEREAS, the undersigned, **Amorsa Therapeutics, Inc.** (hereinafter "**Amorsa**"), having its place of business at 164 Cordaville Road, Suite 628, Southborough, Massachusetts 01772, USA, owns the entire right, title, and interest in and to the patents and patent applications listed in **Exhibit 1** attached hereto (hereinafter, the "**Patents**") and to the inventions described and claimed in the Patents (hereinafter, the "**Inventions**"); and

WHEREAS, the undersigned, **Acadia Pharmaceuticals Inc.** (hereinafter, "**Acadia**"), having its place of business at 12830 El Camino Real, Suite 400, San Diego, California, 92130, USA, desires to acquire the entire right, title and interest to the Patents and the Inventions;

1. **Assignment.** Amorsa hereby irrevocably conveys, transfers and assigns to Acadia, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and Acadia hereby accepts, all of Amorsa's right, title and interest in and to the following:

(a) all rights, privileges and protections of any kind whatsoever of Amorsa accruing under the Inventions and any intellectual property rights therein, provided under the applicable law of any jurisdiction, bylaw, international treaties, conventions or otherwise throughout the world;

(b) the Patents, all patents that issue therefrom, and all continuations, continuations-in-part, divisionals, extensions, substitutions, reissues, re-examinations and renewals, of any of the foregoing, and any patents or patent applications from which any of them claim priority or that claim priority from any of them, and all inventions disclosed and claimed in any of the foregoing, and the right to claim priority to any of the foregoing;

(c) all rights, privileges and protections of any kind whatsoever of Amorsa accruing under any of the Patents provided under the applicable law of any jurisdiction, by international treaties and conventions and otherwise throughout the world, including, but not limited to, the right to file foreign patent applications and license recordings; and

(d) any and all claims and causes of action, with respect to the Inventions or any of the Patents, whether accruing before, on or after the Effective Date, including all rights to and claims for damages, restitution and injunctive and other legal and equitable relief for past, present and future infringement, misappropriation, violation, misuse, breach or default, with the right but no obligation to petition or sue for, or otherwise seek, such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. **Recordation and Further Actions.** Amorsa authorizes the Commissioner for Patents and any other governmental officials to record and register this Agreement upon request by Acadia. Amorsa agrees: (a) to execute (i) all necessary papers throughout the world to be used in connection with the Patents as Acadia may deem necessary or expedient, (ii) all papers in connection with any interference, legal or other proceedings throughout the world to maintain, protect or enforce, or otherwise relating to, the Patents, and (iii) all papers and documents which may be necessary throughout the world in connection with the preparation and filing of any applications for the Invention and the Patents; (b) to cooperate with Acadia at Acadia's expense in every way reasonably possible in obtaining evidence related to the Invention and the Patents going forward in any proceedings related to the Patents throughout the world; and (c) at Acadia's expense to perform all other affirmative acts which in Acadia's reasonable discretion may be necessary or desirable throughout the world to maintain, protect or enforce the Patents. These obligations of assistance by Amorsa shall continue for so long as Acadia may require such assistance from Amorsa.

3. **Counterparts.** This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

4. **Representations and Warranties.** Amorsa represents and warrants to the Acadia that:

(a) Amorsa owns all right and title and interest in the Patents, free and clear of all liens, encumbrances or other obligations;

(b) Amorsa has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder;

(c) the performance of this Agreement will not conflict with any of the Amorsa's existing obligations under any other agreement; and

(d) Amorsa has not granted any licenses to the Patents.

5. **Successors and Assigns.** This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

6. **Governing Law.** This Agreement and any claim, controversy, dispute or cause of action (whether in contract, tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

Agreed to:

AMORSA THERAPEUTICS, INC., as ASSIGNOR

By: 

Date: 6/29/2023

Name: Austin D. Kim

Title: President

Witnessed by:



Date: 6/29/2023

Name: Diane DeWitt

Agreed to:

ACADIA PHARMACEUTICALS INC., as ASSIGNEE

By: ADKim

Date: 6/29/2023

Name: Austin D. Kim

Title: EVP and General Counsel

Witnessed by:

Diane DeWitt

Date: 6/29/2023

Name: Diane DeWitt

EXHIBIT 1**Patents**

Country	Application No.	Patent No.	Filing Date	Title
United States	61/869,884		August 26, 2013	SINGLE-LAYER ORALLY ADMINISTERED TABLET FORMULATIONS OF NEURO- ATTENUATING KETAMINE AND NORKETAMINE
United States	62/015,513		June 22, 2014	SINGLE-LAYER ORALLY ADMINISTERED TABLET FORMULATIONS OF NEURO- ATTENUATING KETAMINE AND NORKETAMINE
Patent Cooperation Treaty	PCT/US2014/052786		August 26, 2014	SINGLE-LAYER ORAL DOSE OF NEURO- ATTENUATING KETAMINE
United States	14/914,416	US 9,913,803 B2	February 25, 2016	SINGLE-LAYER ORAL DOSE OF NEURO- ATTENUATING KETAMINE
United States	15/885,231	US 10,653,629 B2	January 31, 2018	SINGLE-LAYER ORAL DOSE OF NEURO- ATTENUATING KETAMINE
United States	16/868,444	US 11,554,100 B2	May 6, 2020	SINGLE-LAYER ORAL DOSE OF NEURO- ATTENUATING KETAMINE
United States	17/886,944		August 12, 2022	SINGLE-LAYER ORAL DOSE OF NEURO- ATTENUATING KETAMINE
Canada	2922507A	CA 2922507 C	August 26, 2014	SINGLE-LAYER ORAL DOSE OF NEURO- ATTENUATING KETAMINE
Europe	14840272.0	EP 3035918 B1	August 26, 2014	SINGLE-LAYER ORAL DOSE OF NEURO- ATTENUATING KETAMINE

Country	Application No.	Patent No.	Filing Date	Title
Germany	60 2014 078 486.0	EP 3035918 B1	August 26, 2014	SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
France	14840272.0	EP 3035918 B1	August 26, 2014	SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
United Kingdom	14840272.0	EP 3035918 B1	August 26, 2014	SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
Europe	21181816.6		August 26, 2014	SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
Japan	2016537782A		August 26, 2014	SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
Japan	2020016717A		February 4, 2020	SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
United States	62/074,645		November 4, 2014	NEURO-ATTENUATING KETAMINE AND NORKETAMINE, DERIVATIVES THEREOF, AND THEIR USE IN ORAL FORMULATIONS
Patent Cooperation Treaty	PCT/US2015/059113		November 4, 2015	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
United States	15/524,224	US 10,252,982 B2	May 3, 2017	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
United States	16/271,767	US 10,981,859 B2	February 8, 2019	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
United States	17/196,986	US 11,603,348 B2	March 9, 2021	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS

Country	Application No.	Patent No.	Filing Date	Title
United States	17/882,046	US 11,613,515 B2	August 5, 2022	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
United States	18/168,950		February 14, 2023	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
Australia	2015343083A	2015343083 B2	November 4, 2015	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
Canada	2966737A		November 4, 2015	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
China	201580072316A		November 4, 2015	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
China	202211196697.5		November 4, 2015	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
Europe	150856205.8		November 4, 2015	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
Japan	2017543308A	JP 6882180 B2	November 4, 2015	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
Japan	2021078368A		May 6, 2021	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS
Korea	20177015310A		November 4, 2015	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS

Country	Application No.	Patent No.	Filing Date	Title
Russia	2017119222A	RU 2771275 C2	November 4, 2015	NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, THEIR DERIVATIVES, AND METHODS OF THEIR PRODUCTION